Valuation : Interpace Biosciences, Inc.

Market Cap 36.01M 31.03M 29.38M 26.63M 49.96M 3.44B 50.21M 349M 134M 1.75B 135M 132M 5.53B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 34.69M 29.89M 28.3M 25.65M 48.12M 3.31B 48.37M 336M 129M 1.69B 130M 127M 5.33B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day-1.07%
1 week-5.97%
Current month-14.13%
1 month-22.11%
3 months-21.21%
6 months-24.42%
Current year+5.67%
1 week 6.5
Extreme 6.5
6.8
1 month 6.45
Extreme 6.45
8.5
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
50.25
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Free

Director

69,252 0.2501%
20/8/26 Exercice

Chief Financial Officer

1,385,045 5.0015%
20/8/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%-5.97%+58.05%+14.04% 36.01M
+0.86%+0.23%+89.25%+502.55% 47.39B
+1.49%-4.70%+11.38%+54.28% 25.27B
-1.91%-2.76%-15.37%-38.61% 6.73B
+1.63%+2.41%+2.39%+156.68% 5.94B
-0.40%+1.68%+16.26%+71.90% 3.34B
+1.55%-0.84%-32.27%+1,687.53% 2.54B
+12.74%+4.41%+35.00%+45.74% 2.24B
-1.65%-0.35%+107.67%+24.69% 2.23B
-0.73%-2.96%-19.36%-56.60% 1.76B
Average +1.25%-0.76%+25.30%+246.22% 9.75B
Weighted average by Cap. +1.04%-1.05%+48.07%+312.34%

Financials

2024 2025
Net sales 46.93M 40.43M 38.28M 34.7M 65.1M 4.48B 65.43M 455M 175M 2.28B 176M 172M 7.21B 38.73M 33.37M 31.6M 28.64M 53.73M 3.7B 54M 375M 144M 1.88B 145M 142M 5.95B
Net income 6.7M 5.77M 5.47M 4.96M 9.3M 640M 9.34M 64.94M 24.97M 326M 25.17M 24.62M 1.03B 24.58M 21.17M 20.05M 18.17M 34.09M 2.35B 34.26M 238M 91.57M 1.19B 92.29M 90.27M 3.77B
Net Debt 4.4M 3.79M 3.59M 3.25M 6.1M 420M 6.13M 42.58M 16.38M 214M 16.51M 16.14M 675M -1.32M -1.14M -1.08M -978K -1.83M -126M -1.84M -12.81M -4.93M -64.25M -4.96M -4.86M -203M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
11/09/26 USD 6.500 -1.07% 8,249
10/09/26 USD 6.570 +1.08% 2,827
09/09/26 USD 6.500 -5.97% 271
04/09/26 USD 6.913 +6.18% 3,270
03/09/26 USD 6.510 -6.73% 9,471

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXGD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!